At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 28, 2026 at 11:00 ET
Kymera Therapeutics announced positive Phase 1b trial results for KT-621, an oral STAT6 degrader, showing deep target degradation and encouraging clinical activity in patients with moderate-to-severe atopic dermatitis. The data support further development in ongoing Phase 2b trials, with readouts expected by mid-2027 and late-2027.
- KT-621 demonstrated 94% median STAT6 degradation in skin and 98% in blood after 28 days of dosing.
- Robust biomarker reductions: 74% median TARC reduction, up to 73% Eotaxin-3, 56% IL-31, and 14% IgE.
- Clinical improvements: 63% mean EASI reduction, 29% achieved EASI-75, 19% reached vIGA-AD 0/1, 40% peak pruritus NRS reduction.
- KT-621 was well tolerated with a favorable safety profile.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access